Published in Retrovirology on July 25, 2012
Super-resolution microscopy reveals specific recruitment of HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-terminal tail. PLoS Pathog (2013) 1.25
HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis. J Virol (2014) 1.14
Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid. Elife (2014) 1.07
Modelling binding between CCR5 and CXCR4 receptors and their ligands suggests the surface electrostatic potential of the co-receptor to be a key player in the HIV-1 tropism. Retrovirology (2013) 0.85
Cellular superspreaders: an epidemiological perspective on HIV infection inside the body. PLoS Pathog (2014) 0.81
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics. Cancers (Basel) (2017) 0.76
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27
HIV entry and its inhibition. Cell (1998) 9.42
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol (2002) 5.49
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci U S A (2002) 4.52
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med (1995) 4.28
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 3.42
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol (2006) 2.97
Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology (2001) 2.74
Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses (2003) 1.92
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A (1992) 1.89
Coreceptors: implications for HIV pathogenesis and therapy. Science (1997) 1.81
Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol (1988) 1.79
Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev (2003) 1.75
Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev (1994) 1.73
HIV entry inhibitors. Lancet (2007) 1.73
CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother (2005) 1.54
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
Double-labelled HIV-1 particles for study of virus-cell interaction. Virology (2006) 1.49
HIV-1 entry and its inhibition. Curr Top Microbiol Immunol (2003) 1.44
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol (1999) 1.43
Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol (2007) 1.39
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34
Structural perturbation and compensation by directed evolution at physiological temperature leads to thermostabilization of beta-lactamase. Biochemistry (2005) 1.29
Prediction of co-receptor usage of HIV-1 from genotype. PLoS Comput Biol (2010) 1.29
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology (2010) 1.26
Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr (2010) 1.24
Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice. Eur J Med Res (2010) 1.06
Virus entry as a target for anti-HIV intervention. Curr Med Chem (2003) 0.97
Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis (2010) 0.92
Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin (2005) 0.91
Graded cytopathogenicity of the human immunodeficiency virus (HIV) in the course of HIV infection. Med Microbiol Immunol (1990) 0.90
V3 loop sequence space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV. PLoS One (2009) 0.85
Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach. J Vis Exp (2011) 0.84
Light scatter: detection and usage. Curr Protoc Cytom (2001) 0.80
Natural history of HIV-infection in hemophiliacs: clinical, immunological, and virological findings. Klin Wochenschr (1989) 0.77
Bioinformatical assistance of selecting anti-HIV therapies: where do we stand? Intervirology (2012) 0.77
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
ROCR: visualizing classifier performance in R. Bioinformatics (2005) 19.60
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics (2006) 11.33
The protein network of HIV budding. Cell (2003) 7.82
BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics (2005) 5.95
Computing topological parameters of biological networks. Bioinformatics (2007) 5.36
The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol (2004) 4.91
A new measure for functional similarity of gene products based on Gene Ontology. BMC Bioinformatics (2006) 4.82
HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe (2009) 4.36
Structural organization of authentic, mature HIV-1 virions and cores. EMBO J (2003) 4.32
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet (2005) 4.23
The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci U S A (2006) 4.15
The implications of alternative splicing in the ENCODE protein complement. Proc Natl Acad Sci U S A (2007) 3.93
Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol (2007) 3.64
Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci U S A (2002) 3.46
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet (2004) 3.19
HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med (2012) 3.17
The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor. Nat Struct Mol Biol (2005) 3.07
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe (2011) 3.05
CpG island mapping by epigenome prediction. PLoS Comput Biol (2007) 3.02
Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet (2011) 2.98
CpG island methylation in human lymphocytes is highly correlated with DNA sequence, repeats, and predicted DNA structure. PLoS Genet (2006) 2.66
Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell (2011) 2.56
Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49
Calculating the statistical significance of changes in pathway activity from gene expression data. Stat Appl Genet Mol Biol (2004) 2.48
HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog (2007) 2.44
AltAnalyze and DomainGraph: analyzing and visualizing exon expression data. Nucleic Acids Res (2010) 2.41
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res (2003) 2.37
The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. Structure (2006) 2.32
The HIN domain of IFI-200 proteins consists of two OB folds. Biochem Biophys Res Commun (2005) 2.25
Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol (2004) 2.24
A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol (2005) 2.21
The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release. J Virol (2003) 2.19
Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping. Nucleic Acids Res (2008) 2.19
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J Virol (2005) 2.12
Co-clustering of biological networks and gene expression data. Bioinformatics (2002) 2.12
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog (2009) 2.06
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol (2012) 2.03
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med (2007) 1.99
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol (2008) 1.98
In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol (2005) 1.97
Live-cell visualization of dynamics of HIV budding site interactions with an ESCRT component. Nat Cell Biol (2011) 1.96
The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding. J Biol Chem (2004) 1.92
Computational epigenetics. Bioinformatics (2007) 1.92
Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host Microbe (2008) 1.91
BiQ Analyzer HT: locus-specific analysis of DNA methylation by high-throughput bisulfite sequencing. Nucleic Acids Res (2011) 1.90
Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med (2005) 1.88
NOXclass: prediction of protein-protein interaction types. BMC Bioinformatics (2006) 1.85
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A (2013) 1.85
EpiGRAPH: user-friendly software for statistical analysis and prediction of (epi)genomic data. Genome Biol (2009) 1.83
Sialyllactose in viral membrane gangliosides is a novel molecular recognition pattern for mature dendritic cell capture of HIV-1. PLoS Biol (2012) 1.79
Mutations in the NB-ARC domain of I-2 that impair ATP hydrolysis cause autoactivation. Plant Physiol (2006) 1.75
Learning multiple evolutionary pathways from cross-sectional data. J Comput Biol (2005) 1.74
Recco: recombination analysis using cost optimization. Bioinformatics (2006) 1.68
Dynamics of HIV-1 assembly and release. PLoS Pathog (2009) 1.67
Functional evaluation of domain-domain interactions and human protein interaction networks. Bioinformatics (2007) 1.65
DASMI: exchanging, annotating and assessing molecular interaction data. Bioinformatics (2009) 1.64
CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J Virol (2010) 1.63
NEDD4L overexpression rescues the release and infectivity of human immunodeficiency virus type 1 constructs lacking PTAP and YPXL late domains. J Virol (2008) 1.60
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr (2006) 1.53
Computational analysis of human protein interaction networks. Proteomics (2007) 1.53
Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem Biol (2007) 1.52
Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science (2012) 1.50
HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis (2013) 1.49
Double-labelled HIV-1 particles for study of virus-cell interaction. Virology (2006) 1.49
HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem (2009) 1.47
The nephronophthisis gene product NPHP2/Inversin interacts with Aurora A and interferes with HDAC6-mediated cilia disassembly. Nephrol Dial Transplant (2013) 1.47
The molecular architecture of HIV. J Mol Biol (2011) 1.44
Mtreemix: a software package for learning and using mixture models of mutagenetic trees. Bioinformatics (2005) 1.41
EpiExplorer: live exploration and global analysis of large epigenomic datasets. Genome Biol (2012) 1.40
Ultrastructural analysis of ESCRT proteins suggests a role for endosome-associated tubular-vesicular membranes in ESCRT function. Traffic (2006) 1.39
Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol (2007) 1.39
Cryo electron tomography of native HIV-1 budding sites. PLoS Pathog (2010) 1.39
Novel Sm-like proteins with long C-terminal tails and associated methyltransferases. FEBS Lett (2004) 1.38
Improving disease gene prioritization using the semantic similarity of Gene Ontology terms. Bioinformatics (2010) 1.37
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther (2006) 1.37